Sorry, you need to enable JavaScript to visit this website.
Skip to main content
Home

Header Top Menu

  • Careers
  • Investors
  • News
    • Press Release Archive
    • Press Statements
    • Podcasts
      • The Antigen Podcast
      • Get Science Podcast
      • Diverse Perspectives Podcast
      • menopause: unmuted
      • Hemcast
    • Contact Media Relations
    • Press Kits & Downloads
      • Company Press Kit
      • Pfizer Oncology Press Kit
      • PSA Narrative
      • RA NarRAtive
      • Rare Disease Gene Therapy Press Kit
      • ATTR-Amyloidosis Press Kit
      • UC Narrative
      • Eczema Inside Out Press Kit
  • Partners
    • Discovery to Pre-candidate
      • Focus Areas
        • Therapeutic Areas
          • Internal Medicine
          • Inflammation and Immunology
          • Oncology
          • Rare Disease
          • Vaccines
        • Therapeutic Modalities and Technology Platforms
          • Drug Safety
          • Gene Therapy
          • Target Sciences
          • Precision Medicine
          • Medicinal Sciences
            • Biologics Product & Process Development
            • Biotherapeutics Discovery
            • Medicine Design
            • Small Molecule Product & Process Development
        • Emerging Science
          • DNA Damage Response
          • Microsatellite Repeat Expansions
          • Senescence
      • Partnering Models
    • Candidate Through Commercialization
      • Focus Areas
        • Internal Medicine
        • Inflammation and Immunology
        • Oncology
        • Rare Disease
        • Vaccines
        • Hospital
    • Pfizer CentreOne
    • Pfizer Ventures
      • Our portfolio

Healthcare Professionals

  • Healthcare Professionals

Connect with Us

  • Connect with Us
    • Email
    • FAQ
    • Privacy Policy (NEW)
    • YouTube
    • Twitter
    • Facebook
    • LinkedIn
    • Instagram
  • Your Health

    • Healthy Living
      • Brain & Nervous System
      • Cardiovascular Health
      • Cold & Flu
      • Digestive Health
      • Healthier Aging
      • Living Tobacco Free
      • Men’s Health
      • Mental Health
      • Nutrition & Fitness
      • Pediatric Health
      • Respiratory Health
      • Skin Health
      • Vaccines & Prevention
      • Women’s Health

    • Disease & Condition
      • Cancer
      • Cardiovascular Diseases & Conditions
      • Diabetes & Metabolic Disorders
      • Immune System Diseases & Conditions
      • Infections & Infectious Diseases
      • Neurological Diseases & Conditions
      • Menopause
      • Rare Disease
      • Vaccine-Related Conditions
      • Skin Diseases & Conditions
      • Atopic Dermatitis
      • Cardiovascular Disease
      • Severe Hypertriglyceridemia

    • Coronavirus disease (COVID-19) Resources

    • Managing your health
      • Caregiving
      • Evaluating Health Information
      • Tracking Your Health
      • Your Medicines
      • Health Literacy

    • Wellness
    Hot Topics

    Maintaining Emotional Well-Being During COVID-19

    Emotional Well-Being Tips for People Living with Chronic Inflammatory Conditions During COVID-19
  • Our Science

    • Driven to Discover the cure

    • Focus Areas
      • Internal Medicine
      • Inflammation & Immunology
      • Oncology
      • Rare Disease
      • Vaccines
      • Anti Infectives

    • Product Pipeline

    • Clinical Trials
      • Guide to Clinical Trials
      • Find a Trial
      • Expanded Access & Compassionate Use
      • Clinical Trials in Children
      • Partnering with Pfizer
      • Trial Data & Results
      • Research Integrity & Transparency
      • Diversity in Clinical Trials

    • R&D Platforms
      • Biosimilars
      • Gene Therapy
      • Medicinal Sciences
      • Precision Medicine
      • Maternal Immunization

    • Collaboration
      • Partner with Pfizer

    • Research sites

    • Coronavirus disease (COVID-19) Resources
      • All COVID-19 Updates
      • Vaccine Efforts
      • Antiviral Efforts
      • Partnerships & Anti-Infective Efforts
      • Supporting the Fight Against COVID-19
    HOT TOPICS

    MRNA VS. CONVENTIONAL VACCINES

    What Makes an RNA Vaccine Different From a Conventional Vaccine?
  • Our People

    • Meet The Experts
      • Scientists
      • Internal Medicine – Metabolic Disease
      • Inflammation & Immunology
      • Oncology
      • Rare Disease
      • Vaccines
      • Medical Professionals

    • The Journey

    • Leadership
      • Executives
      • Board Members
      • Company Fact Sheet

    • Diverse Perspectives
      • Diversity & Inclusion
      • Supplier Diversity
    HOT TOPICS

    Meet our new Chief Patient Officer, Dr. Dara Richardson-Heron

    dr_richardson_300x170.jpg

    Working Together to Empower Women

    VizagWomen_300x170.jpg

    • Hot Topics
  • Our Purpose

    • Commitment to Global Health
      • Expanding Access
      • Strengthening Health Systems
      • Providing Disaster & Humanitarian Relief
      • Unleashing the Power of Our Colleagues
      • Highlighting Individual Voices

    • Protecting People and the Environment
      • Pfizer's Green Journey
      • Product Stewardship
      • EHS Governance
      • EHS Supply Chain
      • Key Performance Indicators
      • Health & Safety
      • Human Rights

    • Positions on Health Policies
      • Ready for Cures
      • How does Pfizer price medicines?
      • Value of Medicines
      • Policy Positions
      • Creating Cures Through Facility Investments

    • Transparency
      • Working with Health Care Professionals
      • Transparency in Grants
      • Code of Conduct
      • Corporate Compliance
      • Sales and Marketing Compliance

    • Independent Grants
      • Competitive Grants Program
      • Independent Medical Education
      • Investigator Sponsored Research
      • Quality Improvement
      • COVID-19 Vaccine Grants

    • Contributions & Partnerships
      • Healthcare Charitable Contributions
      • Lobbying & Political Contributions
    HOT TOPICS

    Pfizer Women’s Resource Group

    Media Name: IWD_Pull_up_Banner_300x170.jpg

    • Hot Topics
  • Our Products

    • Product listing

    • How drugs are made
      • Branded vs. Generic
      • Biologics & Biosimilars
      • Commitment to Quality

    • Distributors
      • Pfizer Distributors
      • Greenstone Distributors

    • Medicine Safety
      • Reporting Adverse Events
      • Making Good Treatment Choices
      • Partnering With Patients
      • Health Literacy
      • Medicine Safety Tips for Patients
      • Counterfeiting
      • Unused Medicines

    • Safety Data Sheets

    • Medical Information Contacts

    • Pfizer Global Supply
    HOT TOPICS

    Universal vs. Single Payer Healthcare

    Media Name: universal_healthcare300x170.jpg
  • Careers

    • Working Here
      • Mission & Purpose
      • Culture
      • Diversity & Inclusion
      • Career Growth & Colleague Development
      • Compensation & Benefits
      • Ensuring Corporate Responsibility
    • Search Jobs
    • Student & Early Career
      • Postdoctoral Program
      • US Summer Student Worker Program
      • Opportunities for Veterans
    • Pfizer365.com
    • Our Hiring & Recruiting Process
      • Frequently Asked Questions
      • Tips for Interviewing at Pfizer
    • Connect With Us
  • Investors

    • Investors Overview
      • Why Invest / Our Story
      • Prospective Investors
      • Fact Sheet
    • Events & Presentations
    • Financials
      • Quarterly Reports
      • Annual Reports
      • SEC Filings
      • Interactive Data Filings
    • Investor News
    • Stock Information
      • Historical Price Lookup
      • Investment Calculator
      • Historical Stock Chart & Data
      • Dividend & Split History
      • Stock FAQs
    • Governance
      • Board Committees and Charters
      • The Pfizer Board Policies
      • Corporate Governance FAQs
      • Contact Our Directors
    • Shareholder Services
      • Stock FAQs
      • Advisory Information
      • Cost Basis Calculator
  • News

    • Contact Media Relations
    • Podcasts
    • Press Kits & Downloads
    • Press Release Archive
    • Press Statements
  • Partners
  • Footer links

    • Footer Aside Section1
      • CAREER-SEEKERS
      • INVESTORS
      • News & Media
      • Partners
    • Footer Aside Section 2
      • Healthcare Professionals
      • Business To Business
      • Change Region
      • Sitemap
    • Footer Aside Section3
      • Twitter
      • Facebook
      • Linkedin
      • Instagram
      • Youtube
    • Footer Aside Section4
      • Contact Us
      • Terms of Use
      • Privacy Policy

Value of Medicine for Smoking Cessation

Value of Medicine for Smoking Cessation
OUR PURPOSE/ Value of Medicine for Smoking Cessation
July 1, 2016

Tobacco dependence is a chronic and relapsing disease, and cigarette smoking has significant negative health, economic, and social consequences. There are more than one billion smokers globally.1 Based on 2010 figures, more than 300 million people smoke in China (nearly equivalent to the total U.S. population),2 and it is estimated that one in six adults in the United States (U.S.) and one in five in the United Kingdom (U.K.) currently smoke.3,4 By 2030 the total number of smokers globally could reach 2 billion based on current population and smoking trends.5 More than 43 trillion cigarettes were smoked globally in one decade (between 2002 and 2012).6 Tobacco use is also a shared risk factor for the four leading noncommunicable diseases in the world: heart disease/stroke, cancer, diabetes, and chronic respiratory diseases, causing over 6 million deaths annually.7, 17

Adapted from: American Cancer Society. The Tobacco Atlas Fourth Edition. 2012 American Cancer Society, Atlanta GA.

Nicotine Addiction

Regardless of age, people continue to use tobacco because many are addicted to nicotine. Nicotine is one of the primary chemical components of tobacco, and not receiving this chemical leads to unpleasant nicotine withdrawal symptoms.8 Tobacco dependence has been recognized as a disorder by the World Health Organization (WHO).9

Combustion is the most efficient method for nicotine delivery to the brain.7 Smoking addiction results from the pharmacological effects of nicotine.10 When inhaling cigarette smoke, it takes nicotine approximately 10 seconds to reach the brain via the circulatory system. Once in the brain, nicotine disperses and binds to nicotinic acetylcholine receptors (nAChRs). Stimulation of these nAChRs by nicotine releases various neurotransmitters, including dopamine. The release of dopamine produces a pleasurable experience that, along with the desire to avoid the unpleasant experience of withdrawal, helps drive the motivation to smoke and the addiction to nicotine. The prevention of withdrawal symptoms is one of the biggest barriers smokers must overcome to realize abstinence.11,12,13

The reasons people start smoking vary and data suggest virtually all people who smoke start young, by the age of 26.14 Adolescents demonstrate greater sensitivity to the effects of nicotine and require fewer cigarettes to develop nicotine dependence than adults.15 More people in the United States are addicted to nicotine than to any other drug.16

Tobacco is possibly the largest public health threat the world has ever seen, according to the WHO.17

Comorbidities and Economic Burdens of Cigarette Smoking

While the percentage of the population that smokes every day has decreased in recent years, the number of cigarette smokers worldwide has increased due to population growth. Cigarette smoking remains the number one preventable cause of death worldwide, and plays a major role in the development of cardiovascular disease (CVD), chronic obstructive pulmonary disease (COPD), cancer, and pregnancy complications.18,19,20,21

Key facts and figures: Health

  • Six million people die from cigarette smoking each year, and it caused the death of 100 million people in the 20th century alone, according to 2015 data available from the WHO.17
  • Cigarette-related deaths account for more deaths than car accidents, alcohol use, illegal drug use, suicide, homicide, and AIDS combined in the U.S.22

It’s estimated that 85–90 percent of COPD cases can be linked to cigarette smoking and between 15–20 percent of smokers are likely to develop COPD

Source: Jiménez-Ruiz, C. A., Miranda, J. A. R., Gómez, N. A., Blasco, J. J. L., Miñana, J. S., … Ferrero, M. B. (2013). Treatment of smoking in smokers with chronic obstructive pulmonary disease. Arch Bronconeumol, 49, 8, 354-63. Accessed on December 8, 2014 at http://www.archbronconeumol.org/en/treatment-smoking-in-smokers-with/articulo/S1579212913001043/
  • Secondhand smoke, or environmental tobacco smoke (ETS), contributes to more than 600,000 deaths per year globally, according to 2015 data available from the WHO.17 Unless effective campaigns can be instituted to promote smoking cessation, the combination of smoking and aging will vastly increase the rates of cancer and other chronic diseases.5
  • Half of all tobacco users will die prematurely as a result of their tobacco use.17
  • Smoking is responsible for 90 percent of lung cancer related deaths.23
  • Studies have shown that involuntary exposure to secondhand smoke increases the risk of developing coronary heart disease(CHD) by 25 to 30 percent and stroke by 20 to 30 percent.24

Source: Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention. Smoking-attributable mortality, years of potential life lost, and productivity losses— United States, 200–2004. Morbidity and Mortality Weekly Report. 2008;57(45):1226-8.

Key Facts and Figures: Economic

  • The direct costs attributable to smoking totaled $34.8 billion across the U.K., Germany, France, and Spain and $104 billion in the Americas, according to a study published in 2012.6
  • Smokers had significantly higher healthcare, absenteeism, and lost productivity costs than non-smokers, according to a 2013 U.S.-based study.25

Tobacco Control Measures

In 2008, a WHO report found that in developing countries, for every $5,000 in cigarette revenues, only $1 was spent on tobacco control. 26

Many countries realize the detrimental effects that smoking has on their population. As a result, governments have instituted tobacco control strategies to curb its use. For example, the Framework Convention on Tobacco Control (FCTC) was the first global health treaty negotiated under the auspices of the WHO. The FCTC gave a new legal dimension to international health cooperation and became one of the most widely embraced treaties in United Nations history. It aims to save lives through preventing and controlling the use of tobacco products. However, evidence suggests that strategies focusing on prevention alone would provide only minimal reductions in tobacco-related morbidity over the next 20 years.27

Tobacco control has been identified as one of the most rational, evidence-based policies in medicine.28 Tobacco control is defined by WHO as strategies that aim to improve the health of a population by eliminating or reducing their consumption of tobacco products and exposure to tobacco smoke.

These strategies include elements such as:29

  • Pricing and tax measures,
  • Smoking bans (to deter environmental tobacco smoke),
  • Education and awareness campaigns,
  • Access to smoking cessation support and medication,
  • Regulations on advertising and package labeling.

These efforts have helped raise awareness of the benefits of quitting smoking. In early 2015 for example, the Korean government raised the price of tobacco and reinforced its overall smoking cessation policy, including the reimbursement for smoking cessation counseling and treatments.30

Analysis of tobacco control strategies across 18 European countries found that these strategies, despite variations in the level of implementation, resulted in quit ratios between 22.4 and 62.2 percent among men and between 25.0 and 26.9 percent among women who were either former or current smokers aged 25–59 years-old.31 Quit ratios are defined as the number of exsmokers divided by the number of ever smokers (current plus former smokers). A recent study in 41 countries that adopted at least one high-impact reduction measure estimated that the number of smokers dropped by 14.8 million, averting approximately 7.4 million would-be deaths that would have been attributed to smoking.32

While over 90 percent of the 180 parties of the FCTC report that they have implemented at least one priority of the WHO FCTC, over half of them refer to gaps between the financial and human resources available and the needs assessed for implementation. As of 2014, more than half (77) of the parties stated that they seek to ensure the accessibility and affordability of treatment for tobacco dependence, including relevant pharmaceutical products. 33

Full implementation of the Framework Convention would deal the greatest single prevention blow to the four biggest noncommunicable diseases, namely heart disease/stroke, cancer,diabetes, and chronic respiratory diseases.32

Effects of Tobacco Control Policies

  • Based on 2012 data, WHO estimates that by increasing tobacco taxes by 50 percent, all countries would reduce the number of smokers by 49 million within the next three years and ultimately save 11 million lives.34
  • Heart attack admissions rate dropped by 42 percent in the U.K. since a smoking ban was instituted in 2007.35, 36
  • Reviews of 33 out of 44 studies found a significant reduction in heart disease following the introduction of a smoking ban.35,36
  • One year after cessation, a former smoker’s risk of coronary heart disease drops to about half that of a current smoker’s, and after 15 years of abstinence, coronary heart disease risk is equal to those who never smoked.37

 

Source: World Health Organization (WHO). (2016). Tobacco Free initiative (TFI). Who.int. Retrieved from http://www.who.int/tobacco/quitting/benefits/en/

More People Want to Quit

While more people want to quit, it just isn’t that easy. A study conducted by the Centers for Disease Control and Prevention evaluating adults quitting smoking in the U.S. between 2001 and 2010 found that 68.8 percent of all smokers in the U.S. would like to quit. However, a separate study found that 44 percent try to quit each year, mostly without assistance, and that only 4 to 7 percent of smokers who attempted to quit unaided were likely to have succeeded in quitting.38,39 National tobacco control strategies should, therefore, offer access to approved therapies for those desiring to quit,40 as increasing smokers’ access to effective and comprehensive treatment for tobacco dependence can be an effective policy strategy to combat the tobacco epidemic.27

Strategies to Help People Quit

There are currently seven Food and Drug Administration (FDA) approved treatments to help people quit. These include nicotine replacement therapy (NRT), which is available over the counter and by prescription, and non-nicotine prescription medication.

Centers for Disease Control and Prevention. (2016). Smoking & Tobacco Use, Quitting Smoking. Cdc.gov. Retrieved from http://www.cdc.gov/tobacco/data_statistics/fact_sheets/cessation/quitting/. Jamal, A., Dube, S.R., Malarcher, A.M., Shaw, L., Engstrom, M.C. (2012). MMWR, Tobacco use screening and counseling during physician office visits among adults – national ambulatory medical care survey and national health interview survey, United States, 2005-2009. Centers for Disease Control and Prevention, 61, Suppl, 37. Retrieved from http://www.cdc.gov/mmwr/preview/mmwrhtml/su6102a7.htm.

An emerging trend in smoking is the use of electronic cigarettes (also known as e-cigarettes) or electronic nicotine delivery systems(ENDS). These battery-operated devices, which usually resemble a cigarette or pen, transform nicotine and other substances into an inhaled vapor. E-cigarettes’ effectiveness as a smoking cessation product and their long-term effects on public health are not yet known. Organizations like the American Lung Association have expressed concern about their potential health risks.41

Research to better understand the pathophysiology of nicotine addiction is ongoing, as are efforts to reduce the harmful effects of smoking. Innovations in smoking cessation therapy include research into anti-nicotine vaccines and novel delivery mechanisms.

Cigarette smoking is deadly, and for those desiring to quit, research suggests that the best way for people to quit smoking is through evidence-based smoking cessation technologies and programs.42 Advances in smoking cessation and tobacco control policies, combined with smoking cessation therapies, are necessary to reverse a global health epidemic. The potential value to improved human health and disease prevention is massive and warrants furthering these advancements in smoking cessation.

References

  1. Jha,P. (2009). Avoidable global cancer deaths and total deaths from smoking. Nat. Rev. Cancer, 9, 655–664. Retrieved from http://www.nature.com/nrc/journal/v9/n9/full/nrc2703.html.
  2. Yang, L., Sung, H., Mao, Z., Hu, T., Rao K. (2011). Economic costs attributable to smoking in China: update and an 8-year comparison, 2000-2008. Tobacco Control, 20, 266-72. Retrieved from http://www.cancerresearchuk.org/cancer-info/cancerstats/causes/lifestyle/tobacco/.
  3. Thun, M.J., DeLancey, J.O., Center, M.M., Jemal, A., Ward, E.M. (2010). The global burden of cancer: priorities for prevention. Carcinogenesis, 1, 100-110. Retrieved from http://www.drugabuse.gov/publications/research-reports/tobacco-addiction/nicotine-addictive.
  4. World Health Organization. (2010). International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10). Retrieved from http://www.itcproject. orghttps://cdn.pfizer.com/pfizercom/Article/itccessationreport.pdf.
  5. Bettcher, D., Yach, D., Guindon, E.G. (2000). Global trade and health: key linkages and future challenges. Bulletin of the World Health Organization, 78, 521–34. Retrieved from http://www.ncbi.nlm.nih.gov/ pmc/articles/PMC2560735/.
  6. World Health Organization. (2005). WHO Framework Convention on tobacco control. Who.int. Retrieved from http://www.who.int/tobacco/framework/WHO_FCTC_english.pdf.
  7. Kato, Koichi (March 9, 2015). Nikkei, Asian Review, Politics and Economy. Cigarettes nearly double in price. Retrieved from http://asia.nikkei.com/Politics-Economy/Economy/Cigarettes-nearly-double-in-price
  8. Schapp, M.M., Junst, A.E., Leinsalu, M., Regidor, E., Ekholm, O. Dzurova, D., … Mackenbach, J.P. (2008). Effect of nation-wide tobacco control policies on smoking cessation in high and low educated groups
  9. Chan, M. (2015). Address at an event celebrating the 10th anniversary of the WHO Framework Convention on Tobacco Control. Who.int. Retrieved from http://www.who.int/dg/speeches/2015/10thanniversary-fctc/en/.
  10. World Health Organization. (2014). 2014 global progress report on implantation of the WHO Framework Convention on tobacco control. Who.int. Retrieved from http://www.who.int/fctc/ reporting/2014globalprogressreport.pdf?ua=1.
  11. World Health Organization. (2014). WHO calls for higher tobacco taxes to save more lives. Who int. Retrieved from http://www.who.int/mediacentre/news/releases/2014/no-tobacco-day/en/.
  12. Donnelly, L. (2016). Smoking ban sees 40 per cent cut in heart attacks in UK since 2007 law was introduced. The Daily Telegraph. Retrieved from http://www.telegraph.co.uk/news/health/news/12138413/ Smoking-ban-sees-40-per-cent-cut-in-heart-attacks-since-2007-law-was-introduced.html.
  13. Liu A, Guzman Castillo M, Capewell S, et al. Reduction in myocardial infarction admissions in Liverpool after the smoking ban: potential socioeconomic implications for policymaking. BMJ Open 2013;3:e003307. doi:10.1136/bmjopen-2013-003307
  14. World Health Organization. (2016). Tobacco Free Initiative (TFI), fact sheet about health benefits of smoking cessation. Who.int. Retrieved from http://www.who.int/tobacco/quitting/benefits/en/.
  15. Centers for Disease Control and Prevention. (2016). Smoking & Tobacco Use, Quitting Smoking. Cdc.gov. Retrieved from http://www.cdc.gov/tobacco/data_statistics/fact_sheets/cessation/quitting/.
  16. Jamal, A., Dube, S.R., Malarcher, A.M., Shaw, L., Engstrom, M.C. (2012). MMWR, Tobacco use screening and counseling during physician office visits among adults – national ambulatory medical care survey and national health interview survey, United States, 2005-2009. Centers for Disease Control and Prevention, 61, Suppl, 37. Retrieved from http://www.cdc.gov/mmwr/preview/mmwrhtml/su6102a7.htm.
  17. The World Bank. (1999) Curbing the epidemic, governments and the economics of tobacco control. The International Bank for Reconstruction and Development. Retrieved from http://www.cghr.org/ wordpress/wp-content/uploads/Curbing-the-Epidemic-Tobacco-Control-World-Bank-1999-Prabhat-Jha.pdf.
  18. American Lung Association. (2016). E-cigarettes and lung health. Lung.org. Retrieved from http://www.lung.org/stop-smoking/smoking-facts/e-cigarettes-and-lung-health.html.
  19. Institute of Medicine of the National Academics. (2016). Smoking Cessation Programs. Nationalacademies.org. Retrieved from http://sites.nationalacademies.org/Tobacco/SmokingCessation/ TOBACCO_051286. 

Issued by Global Policy and International Public Affairs

 pfizer-rxpathways-logo

Download this Smoking Cessation article in PDF format.

Key Takeaways

Tobacco is possibly the largest public health threat the world has ever seen.17


Cigarette smoking is the No. 1 preventable cause of death.18


Each year 6 million people die from cigarette smoking.17


Access to effective and comprehensive treatment for tobacco dependence is a proven policy strategy to reverse the tobacco epidemic.42

Related Hot Topics
Media Name: vom_cholesterol300x170.jpg
Value of Cholesterol Lowering Medications
The Smoking Epidemic: A Snapshot
The Smoking Epidemic: A Snapshot
vom_stroke_300x170.jpg
Value of Medicines Stroke and Atrial Fibrillation
The Value Of Medicines for Type 2 Diabetes
The Value Of Medicines for Type 2 Diabetes
Tags
Smoking
Value of Medicines Metabolic
Show
Hide

Footer menu

  • Your Health
    • Healthy Living
    • Disease Conditions
    • Manage Your Health
  • Our Science
    • Therapeutic Areas
    • Product Pipeline
    • Clinical Trials
    • R&D Platforms
    • Collaboration
    • Research SItes
  • Our People
    • Meet the Experts
    • The Journey
    • Leadership
    • Diverse Perspectives
  • Our Purpose
    • Commitment To Global Health
    • Positions on Health Policies
    • Transparency
    • Contributions & Partnerships
  • Our Products
    • Product Listing
    • How Drugs are Made
    • Distributors
    • Global Product Information Contacts

Footer aside

  • Footer Aside Section1
    • CAREER-SEEKERS
    • INVESTORS
    • News & Media
    • Partners
  • Footer Aside Section 2
    • Healthcare Professionals
    • Business To Business
    • Change Region
    • Sitemap
  • Footer Aside Section3
    • Twitter
    • Facebook
    • Linkedin
    • Instagram
    • Youtube
  • Footer Aside Section4
    • Contact Us
    • Terms of Use
    • Privacy Policy
Pfizer Logo Footer

Copyright © 2002-2021 Pfizer Inc. All rights reserved. This information—including product information—is intended only for residents of the United States.
The products discussed herein may have different labeling in different countries.